Maxim Group assumed coverage on shares of Digirad (NASDAQ:DRAD) in a research note issued to investors on Friday morning, reports. The firm issued a buy rating and a $6.00 target price on the medical equipment provider’s stock.

Shares of NASDAQ DRAD opened at $2.56 on Friday. Digirad has a twelve month low of $1.99 and a twelve month high of $8.84. The stock’s 50 day moving average price is $2.67 and its 200-day moving average price is $2.95. The company has a market capitalization of $12.03 million, a PE ratio of -0.75 and a beta of 0.42. The company has a quick ratio of 1.04, a current ratio of 1.36 and a debt-to-equity ratio of 1.05.

Digirad (NASDAQ:DRAD) last announced its earnings results on Thursday, August 13th. The medical equipment provider reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $1.31. Digirad had a negative return on equity of 1.40% and a negative net margin of 5.19%. The firm had revenue of $22.34 million for the quarter.

An institutional investor recently bought a new position in Digirad stock. Two Sigma Advisers LP bought a new stake in Digirad Co. (NASDAQ:DRAD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 49,700 shares of the medical equipment provider’s stock, valued at approximately $139,000. Two Sigma Advisers LP owned about 1.06% of Digirad as of its most recent SEC filing. 11.58% of the stock is owned by institutional investors.

Digirad Company Profile

Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services.

See Also: Can systematic risk be avoided?

Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with's FREE daily email newsletter.